COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING FOR GENOVIS AB (PUBL) NOVEMBER 19, 2013

The Extraordinary General Meeting decided upon a rights issue to existing
shareholders in which three (3) existing shares entitle the holder to
subscription for one (1) new share at a subscription price of SEK 4.50/ share.
The share capital could increase by a maximum of SEK 2,104,100.80 through the
issuance of up to 5,260,252 shares.

Timetable for new issue

Nov. 25, 2013   Last trading day for Genovis share, including subscription
rights for new issue.

Nov. 28, 2013   Record date for participation in the new issue; shareholders
registered in Genovis’ share register on this day receive subscription rights
for participation in the new issue.

Dec. 2 – Dec. 16, 2013   Subscription period. Subscription with preferential
rights through cash payment during the subscription period. Shareholders may
report their intention to subscribe throughout the subscription period.

The Extraordinary General Meeting resolve to authorize the Board, provided that
the rights issue for a maximum of 5,260,252 shares is fully subscribed, on one
or more occasions, to decide on the issuance of a total of a maximum of
1,350,000 shares in the Company with or without preferential rights for the
Companyʼs shareholders. The subscription price will be four Swedish kronor and
fifty öre (SEK 4.50), payment for subscribed shares shall be made in cash, and
the Board will have the option to permit set-offs retroactively. This
authorization will be valid for the period ending on January 20, 2014.

The reason for any deviation from shareholdersʼ preferential rights is to be
able to take advantage of attracting interest from potential underwriters within
the framework for issued underwriting guarantees.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00